http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008051373-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662 |
| filingDate | 2007-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f560e2ce52cc3d22c377009d192f4f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1003bd077e443898b6c3854d6c4b5cc8 |
| publicationDate | 2008-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2008051373-A1 |
| titleOfInvention | Parenteral preparations of GI-safer phospholipid-associated anti-inflammatories and methods of preparation and use |
| abstract | Parenteral preparations of phospholipid-associated anti-inflammatories (PL-AIs) are described to treat pain/inflammation, with reduced gastrointestinal (GI) toxicity. The PL-AIs can be composed of phosphatidylcholine (“PC”) associated with non-steroidal anti-inflammatory drugs (“NSAIDs”). To prepare the PL-AIs, a phospholipid is mixed with an NSAID in a polar solvent, solvent is removed, suspended in an aqueous medium and sterilized by filtration or other acceptable method. Alternatively, the phospholipid can be mixed with an injectable preparation of an NSAID. The PL-AIs, and particularly PC associated with the NSAIDs, indomethacin, ibuprofen or diclofenac are useful for treating Patent Ductus Arteriosus in low birth weight infants to reduce the incidence of GI injury that may be manifest as Necrotizing Enterocolitis (NEC) or Spontaneous Intestinal Perforation (SIP). Other applications of the parenteral PL-AIs include prevention of: retinopathy of prematurity; and of pain from conditions associated with surgery, trauma, Sickle Cell Anemia and neural inflammation/injury. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10369101-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009073630-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021260014-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009143762-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008008745-A1 |
| priorityDate | 2003-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 281.